FULVESTRANT SANDOZ fulvestrant 250 mg/5 mL solution for injection in pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

fulvestrant sandoz fulvestrant 250 mg/5 ml solution for injection in pre-filled syringe

sandoz pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: castor oil; benzyl alcohol; benzyl benzoate; ethanol - fulvestrant sandoz is indicated for the treatment of postmenopausal women with: ? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

Fulvestrant Accord 250 mg inj. sol. i.m. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fulvestrant accord 250 mg inj. sol. i.m. pre-filled syr.

accord healthcare b.v. - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Fulvestrant Sandoz 250 mg inj. sol. i.m. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fulvestrant sandoz 250 mg inj. sol. i.m. pre-filled syr.

sandoz sa-nv - fulvestrant 250 mg/5 ml - solution for injection - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Fulvestrant Ever Pharma 250 mg inj. sol. i.m. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fulvestrant ever pharma 250 mg inj. sol. i.m. pre-filled syr.

ever valinject gmbh - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Fulvestrant Fresenius Kabi 250 mg inj. sol. i.m. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fulvestrant fresenius kabi 250 mg inj. sol. i.m. pre-filled syr.

fresenius kabi sa-nv - fulvestrant 250 mg - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant

Fulvestrant EVER Pharma 250 mg solution for injection in pre-filled syringe Ireland - English - HPRA (Health Products Regulatory Authority)

fulvestrant ever pharma 250 mg solution for injection in pre-filled syringe

ever valinject gmbh - fulvestrant - solution for injection in pre-filled syringe - 250 milligram(s) - fulvestrant

FULVESTRANT 250 MG S.K. Israel - English - Ministry of Health

fulvestrant 250 mg s.k.

k.s.kim international (sk- pharma) ltd., israel - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapy fulvestrant is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or - with disease relapse on or after adjuvant endocrine therapy; or - disease progression on endocrine therapy combination therapy fulvestrant is indicated for the treatment of: - hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. - hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Fulvestrant-Teva New Zealand - English - Medsafe (Medicines Safety Authority)

fulvestrant-teva

teva pharma (new zealand) limited - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age, previously treated with endocrine therapy (antioestrogen or aromatase inhibitor therapy), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Fulvestrant 250 mg solution for injection in pre-filled syringe Ireland - English - HPRA (Health Products Regulatory Authority)

fulvestrant 250 mg solution for injection in pre-filled syringe

reddy holding gmbh - fulvestrant - solution for injection in pre-filled syringe - fulvestrant

Fulvestrant Rowex 250 mg/5 ml solution for injection in pre-filled syringe Ireland - English - HPRA (Health Products Regulatory Authority)

fulvestrant rowex 250 mg/5 ml solution for injection in pre-filled syringe

rowex ltd - fulvestrant - solution for injection in pre-filled syringe - 250 mg/5ml - anti-estrogens; fulvestrant